PPA1 Deficiency Causes a Deranged Galactose Metabolism Recognizable in Neonatal Screening
Two siblings showed increased galactose and galactose-related metabolites in neonatal screening. Diagnostic workup did not reveal abnormalities in any of the known disease-causing enzymes involved in galactose metabolism. Using whole-exome sequencing, we identified a homozygous missense variant in &...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-11-01
|
| Series: | Metabolites |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-1989/13/11/1141 |
| _version_ | 1827639303464812544 |
|---|---|
| author | Melanie T. Achleitner Judith J. M. Jans Laura Ebner Johannes Spenger Vassiliki Konstantopoulou René G. Feichtinger Karin Brugger Doris Mayr Ron A. Wevers Christian Thiel Saskia B. Wortmann Johannes A. Mayr |
| author_facet | Melanie T. Achleitner Judith J. M. Jans Laura Ebner Johannes Spenger Vassiliki Konstantopoulou René G. Feichtinger Karin Brugger Doris Mayr Ron A. Wevers Christian Thiel Saskia B. Wortmann Johannes A. Mayr |
| author_sort | Melanie T. Achleitner |
| collection | DOAJ |
| description | Two siblings showed increased galactose and galactose-related metabolites in neonatal screening. Diagnostic workup did not reveal abnormalities in any of the known disease-causing enzymes involved in galactose metabolism. Using whole-exome sequencing, we identified a homozygous missense variant in <i>PPA1</i> encoding the cytosolic pyrophosphatase 1 (PPA1), c.557C>T (p.Thr186Ile). The enzyme activity of PPA1 was determined using a colorimetric assay, and the protein content was visualized via western blotting in skin fibroblasts from one of the affected individuals. The galactolytic activity of the affected fibroblasts was determined by measuring extracellular acidification with a Seahorse XFe96 analyzer. PPA1 activity decreased to 22% of that of controls in the cytosolic fraction of homogenates from patient fibroblasts. PPA1 protein content decreased by 50% according to western blot analysis, indicating a reduced stability of the variant protein. The extracellular acidification rate was reduced in patient fibroblasts when galactose was used as a substrate. Untargeted metabolomics of blood samples revealed an elevation of other metabolites related to pyrophosphate metabolism. Besides hyperbilirubinemia in the neonatal period in one child, both children were clinically unremarkable at the ages of 3 and 14 years, respectively. We hypothesize that the observed metabolic derangement is a possible mild manifestation of PPA1 deficiency. Unresolved abnormalities in galactosemia screening might result in the identification of more individuals with PPA1 deficiency, a newly discovered inborn metabolic disorder (IMD). |
| first_indexed | 2024-03-09T16:37:37Z |
| format | Article |
| id | doaj.art-dc3aef11382044e895ecfc7cc14db061 |
| institution | Directory Open Access Journal |
| issn | 2218-1989 |
| language | English |
| last_indexed | 2024-03-09T16:37:37Z |
| publishDate | 2023-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Metabolites |
| spelling | doaj.art-dc3aef11382044e895ecfc7cc14db0612023-11-24T14:55:28ZengMDPI AGMetabolites2218-19892023-11-011311114110.3390/metabo13111141PPA1 Deficiency Causes a Deranged Galactose Metabolism Recognizable in Neonatal ScreeningMelanie T. Achleitner0Judith J. M. Jans1Laura Ebner2Johannes Spenger3Vassiliki Konstantopoulou4René G. Feichtinger5Karin Brugger6Doris Mayr7Ron A. Wevers8Christian Thiel9Saskia B. Wortmann10Johannes A. Mayr11University Children’s Hospital, Salzburger Landeskliniken (SALK), Paracelsus Medical University, 5020 Salzburg, AustriaDepartment of Genetics, University Medical Center Utrecht, Utrecht University, 3584 CX Utrecht, The NetherlandsUniversity Children’s Hospital, Salzburger Landeskliniken (SALK), Paracelsus Medical University, 5020 Salzburg, AustriaUniversity Children’s Hospital, Salzburger Landeskliniken (SALK), Paracelsus Medical University, 5020 Salzburg, AustriaDepartment of Pediatrics, Austrian Newborn Screening, Medical University of Vienna, 1090 Vienna, AustriaUniversity Children’s Hospital, Salzburger Landeskliniken (SALK), Paracelsus Medical University, 5020 Salzburg, AustriaUniversity Children’s Hospital, Salzburger Landeskliniken (SALK), Paracelsus Medical University, 5020 Salzburg, AustriaUniversity Children’s Hospital, Salzburger Landeskliniken (SALK), Paracelsus Medical University, 5020 Salzburg, AustriaDepartment of Human Genetics, Translational Metabolic Laboratory, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, 6525 GA Nijmegen, The NetherlandsCenter for Child and Adolescent Medicine, Pediatrics I, University Heidelberg, Analysezentrum 3, 69120 Heidelberg, GermanyUniversity Children’s Hospital, Salzburger Landeskliniken (SALK), Paracelsus Medical University, 5020 Salzburg, AustriaUniversity Children’s Hospital, Salzburger Landeskliniken (SALK), Paracelsus Medical University, 5020 Salzburg, AustriaTwo siblings showed increased galactose and galactose-related metabolites in neonatal screening. Diagnostic workup did not reveal abnormalities in any of the known disease-causing enzymes involved in galactose metabolism. Using whole-exome sequencing, we identified a homozygous missense variant in <i>PPA1</i> encoding the cytosolic pyrophosphatase 1 (PPA1), c.557C>T (p.Thr186Ile). The enzyme activity of PPA1 was determined using a colorimetric assay, and the protein content was visualized via western blotting in skin fibroblasts from one of the affected individuals. The galactolytic activity of the affected fibroblasts was determined by measuring extracellular acidification with a Seahorse XFe96 analyzer. PPA1 activity decreased to 22% of that of controls in the cytosolic fraction of homogenates from patient fibroblasts. PPA1 protein content decreased by 50% according to western blot analysis, indicating a reduced stability of the variant protein. The extracellular acidification rate was reduced in patient fibroblasts when galactose was used as a substrate. Untargeted metabolomics of blood samples revealed an elevation of other metabolites related to pyrophosphate metabolism. Besides hyperbilirubinemia in the neonatal period in one child, both children were clinically unremarkable at the ages of 3 and 14 years, respectively. We hypothesize that the observed metabolic derangement is a possible mild manifestation of PPA1 deficiency. Unresolved abnormalities in galactosemia screening might result in the identification of more individuals with PPA1 deficiency, a newly discovered inborn metabolic disorder (IMD).https://www.mdpi.com/2218-1989/13/11/1141PPA1pyrophosphategalactosemiagalactosehyperbilirubinemiainborn metabolic disorder |
| spellingShingle | Melanie T. Achleitner Judith J. M. Jans Laura Ebner Johannes Spenger Vassiliki Konstantopoulou René G. Feichtinger Karin Brugger Doris Mayr Ron A. Wevers Christian Thiel Saskia B. Wortmann Johannes A. Mayr PPA1 Deficiency Causes a Deranged Galactose Metabolism Recognizable in Neonatal Screening Metabolites PPA1 pyrophosphate galactosemia galactose hyperbilirubinemia inborn metabolic disorder |
| title | PPA1 Deficiency Causes a Deranged Galactose Metabolism Recognizable in Neonatal Screening |
| title_full | PPA1 Deficiency Causes a Deranged Galactose Metabolism Recognizable in Neonatal Screening |
| title_fullStr | PPA1 Deficiency Causes a Deranged Galactose Metabolism Recognizable in Neonatal Screening |
| title_full_unstemmed | PPA1 Deficiency Causes a Deranged Galactose Metabolism Recognizable in Neonatal Screening |
| title_short | PPA1 Deficiency Causes a Deranged Galactose Metabolism Recognizable in Neonatal Screening |
| title_sort | ppa1 deficiency causes a deranged galactose metabolism recognizable in neonatal screening |
| topic | PPA1 pyrophosphate galactosemia galactose hyperbilirubinemia inborn metabolic disorder |
| url | https://www.mdpi.com/2218-1989/13/11/1141 |
| work_keys_str_mv | AT melanietachleitner ppa1deficiencycausesaderangedgalactosemetabolismrecognizableinneonatalscreening AT judithjmjans ppa1deficiencycausesaderangedgalactosemetabolismrecognizableinneonatalscreening AT lauraebner ppa1deficiencycausesaderangedgalactosemetabolismrecognizableinneonatalscreening AT johannesspenger ppa1deficiencycausesaderangedgalactosemetabolismrecognizableinneonatalscreening AT vassilikikonstantopoulou ppa1deficiencycausesaderangedgalactosemetabolismrecognizableinneonatalscreening AT renegfeichtinger ppa1deficiencycausesaderangedgalactosemetabolismrecognizableinneonatalscreening AT karinbrugger ppa1deficiencycausesaderangedgalactosemetabolismrecognizableinneonatalscreening AT dorismayr ppa1deficiencycausesaderangedgalactosemetabolismrecognizableinneonatalscreening AT ronawevers ppa1deficiencycausesaderangedgalactosemetabolismrecognizableinneonatalscreening AT christianthiel ppa1deficiencycausesaderangedgalactosemetabolismrecognizableinneonatalscreening AT saskiabwortmann ppa1deficiencycausesaderangedgalactosemetabolismrecognizableinneonatalscreening AT johannesamayr ppa1deficiencycausesaderangedgalactosemetabolismrecognizableinneonatalscreening |